GlassScriptPhysician profile
Farzan M Gorgani
NPI 1497133615
$10,561.78
in general payments reported to CMS, 2019-2025
27 companies · $1,781 in 2025
The $1,781 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $215 · 2021: $883 · 2022: $2,031 · 2023: $2,060 · 2024: $1,432 · 2025: $1,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507 · Travel and Lodging: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,506.75 |
| Travel and Lodging | $766.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,066.25 | 2019-2025 | Tecnis Simplicity |
| Biotissue Holdings INC. | $1,481.93 | 2021-2025 | |
| Alcon Vision LLC | $814.15 | 2019-2025 | Clareon, Simbrinza, Tryptyr |
| Oyster Point Pharma, INC. | $769.50 | 2022-2025 | Tyrvaya |
| Horizon Therapeutics Plc | $615.67 | 2020-2023 | Tepezza |
| Amgen INC. | $510.68 | 2024-2025 | Tepezza |
| Allergan, INC. | $509.40 | 2020-2022 | |
| Abbvie INC. | $474.90 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $456.84 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $399.82 | 2023-2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $351.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $344.91 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| New World Medical,INC. | $255.90 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $215.51 | 2019-2020 | |
| Ivantis, INC | $215.42 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $190.08 | 2019-2022 | |
| Dompe US, INC. | $189.78 | 2021-2025 | Oxervate |
| Ani Pharmaceuticals, INC. | $168.83 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Harrow Eye, LLC | $155.43 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $131.66 | 2019-2025 | |
| Ocular Therapeutix, INC. | $50.35 | 2025 | Dextenza |
| Glaukos Corporation | $48.13 | 2019-2025 | Photrexa Viscous and Photrexa |
| Beaver-Visitec International, INC. | $38.75 | 2021 | |
| Eyevance Pharmaceuticals LLC | $35.79 | 2022 | |
| Kala Pharmaceuticals, INC. | $28.91 | 2022 | |
| Apellis Pharmaceuticals, INC. | $23.68 | 2025 | Syfovre |
| Genentech USA, INC. | $18.49 | 2025 | Vabysmo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farzan Gorgani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.